A Real World Study of Treatment Regimens Containing Camrelizumab in Patients With Advanced Liver Cancer
Latest Information Update: 06 Apr 2022
At a glance
- Drugs Camrelizumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 20 Mar 2022 Planned End Date changed from 1 Mar 2023 to 1 Jan 2025.
- 20 Mar 2022 Planned primary completion date changed from 1 Sep 2021 to 1 Jan 2023.
- 20 Mar 2022 Status changed from not yet recruiting to recruiting.